Tan Zhongbao, Wu Daguang, Guo Jinhe, Wang Huanjing, Zhang Jian
Department of Interventional Radiology, The Affiliated Hospital of Jiangsu University, Jiangsu University, Zhenjiang, Jiangsu, China.
Department of Oncology, Funing County People's Hospital, Yancheng, Jiangsu, China.
Front Oncol. 2023 Jul 18;13:1201381. doi: 10.3389/fonc.2023.1201381. eCollection 2023.
The aim of this study is to investigate the feasibility and effectiveness of endovascular brachytherapy with iodine-125 (I-125) seed strand for the treatment of extensive portal vein tumor thrombus (PVTT) in hepatocellular carcinoma (HCC) patients.
A total of 40 HCC patients complicated by extensive PVTT who received I-125 seed strand implantation from January 2015 to December 2022 in our center were analyzed retrospectively. Endpoints included technical success rate, concurrent therapies, overall survival time, and complications. Multivariate and subgroup analyses were conducted for overall survival.
The successful rate of operation was 100%, and there was no operation-related death. A total of 37 patients received single I-125 seed strand implantation, and three patients received double I-125 seed strand implantation. A total of 23 patients received a concurrent therapy: transarterial chemoembolization (TACE) combined with systematic treatment (n = 6), TACE alone (n = 10), and systematic treatment alone (n = 9). At a median follow-up of 3.5 (interquartile range (IQR), 28.5) months, the median overall survival (OS) of all patients was 92 days (95% confidence interval (CI): 77108). In the subgroup analysis, the median OS was 128 days (95% CI: 101155 days) in the I-125 seed strand implantation plus systematic treatment group and was longer than that (75 days (95% CI: 36114) of the I-125 seed strand alone group ( = 0.037). Multivariate analysis revealed that no systematic treatment was an independent risk factor affecting the prognosis in this study. Six patients died of upper gastrointestinal bleeding: four patients in the I-125 seed strand alone group and two patients in the combination of I-125 seed strand with systematic treatment group.
The study shows that endovascular brachytherapy with I-125 seed strand implantation is a safe and effective treatment method for extensive PVTT in HCC patients. The combination of I-125 seed strand implantation and systematic treatment can prolong the survival time.
本研究旨在探讨碘-125(I-125)籽源链血管内近距离治疗肝细胞癌(HCC)患者广泛性门静脉肿瘤血栓(PVTT)的可行性和有效性。
回顾性分析2015年1月至2022年12月在本中心接受I-125籽源链植入的40例合并广泛性PVTT的HCC患者。观察指标包括技术成功率、同期治疗情况、总生存时间和并发症。对总生存进行多因素和亚组分析。
手术成功率为100%,无手术相关死亡。共37例患者接受单根I-125籽源链植入,3例患者接受双根I-125籽源链植入。共23例患者接受同期治疗:经动脉化疗栓塞术(TACE)联合全身治疗(n = 6)、单纯TACE(n = 10)、单纯全身治疗(n = 9)。中位随访3.5(四分位间距(IQR),28.5)个月,所有患者的中位总生存(OS)时间为92天(95%置信区间(CI):77108)。亚组分析中,I-125籽源链植入联合全身治疗组的中位OS为128天(95%CI:101155天),长于单纯I-125籽源链组(75天(95%CI:36114),P = 0.037)。多因素分析显示,未接受全身治疗是本研究中影响预后的独立危险因素。6例患者死于上消化道出血:单纯I-125籽源链组4例,I-125籽源链联合全身治疗组2例。
本研究表明,I-125籽源链植入血管内近距离治疗是HCC患者广泛性PVTT的一种安全有效的治疗方法。I-125籽源链植入联合全身治疗可延长生存时间。